Both parts matter, but you are right it wouldn't be significantly cheaper to do the transnational and regulatory stuff publicly or by non-profits.

What probably would change is the choices on which conditions and drugs to target, and to what degree. Conceivably could shift from an ability-to-pay focus to an impact focus.

Exercise left to the reader to decide if that would be desirable and/or likely to be more successful overall.